Bank of New York Mellon Corp Lowers Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Bank of New York Mellon Corp reduced its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 18.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 226,299 shares of the company's stock after selling 49,932 shares during the period. Bank of New York Mellon Corp owned approximately 0.26% of IDEAYA Biosciences worth $5,816,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. FMR LLC raised its stake in IDEAYA Biosciences by 12.1% during the 3rd quarter. FMR LLC now owns 12,635,653 shares of the company's stock valued at $400,297,000 after acquiring an additional 1,365,570 shares during the last quarter. RA Capital Management L.P. acquired a new position in shares of IDEAYA Biosciences in the third quarter valued at approximately $42,681,000. Janus Henderson Group PLC raised its stake in shares of IDEAYA Biosciences by 26.7% during the third quarter. Janus Henderson Group PLC now owns 5,162,376 shares of the company's stock worth $163,518,000 after purchasing an additional 1,086,356 shares during the last quarter. Jennison Associates LLC lifted its holdings in shares of IDEAYA Biosciences by 136.6% during the third quarter. Jennison Associates LLC now owns 972,266 shares of the company's stock worth $30,801,000 after purchasing an additional 561,404 shares during the period. Finally, State Street Corp grew its position in IDEAYA Biosciences by 15.4% in the 3rd quarter. State Street Corp now owns 3,317,936 shares of the company's stock valued at $105,112,000 after buying an additional 443,640 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

IDYA has been the subject of several recent analyst reports. Stephens restated an "overweight" rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Royal Bank of Canada restated an "outperform" rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Wedbush reiterated an "outperform" rating and set a $52.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, December 17th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Two research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, IDEAYA Biosciences currently has an average rating of "Moderate Buy" and a consensus price target of $53.58.

IDEAYA Biosciences Stock Performance

NASDAQ:IDYA traded up $0.55 during mid-day trading on Monday, hitting $19.13. 587,508 shares of the company's stock traded hands, compared to its average volume of 820,209. The firm's 50 day simple moving average is $21.95 and its 200 day simple moving average is $27.15. The company has a market cap of $1.67 billion, a PE ratio of -5.80 and a beta of 0.76. IDEAYA Biosciences, Inc. has a 1 year low of $16.95 and a 1 year high of $46.40.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.82). The company had revenue of $7.00 million during the quarter, compared to analysts' expectations of $7.00 million. On average, research analysts expect that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.